AACP
ORGO icon

Advantage Alpha Capital Partners’s Organogenesis Holdings ORGO Stock Holding History

Advantage Alpha Capital Partners’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-101,558
Closed -$290K – 175
2024
Q3 		$290K Sell
101,558
-256,896
-72% -$720K 0.07% 158
2024
Q2 		$1M Sell
358,454
-37,662
-10% -$101K 0.22% 85
2024
Q1 		$1.12M Buy
+396,116
New +$1.35M 0.21% 94

Other funds holding ORGO

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advantage Alpha Capital Partners's ORGO Position: Q4 2024 in Review

Advantage Alpha Capital Partners sold out of Organogenesis Holdings (ORGO) in Q4 2024, closing a stake of 101,558 shares — an estimated $290K sold.

Advantage Alpha Capital Partners first reported a position in ORGO in Q1 2024 and held it in 3 quarters. The position peaked at $1.12M in Q1 2024. 120 funds tracked by Wall St. Rank hold ORGO as of Q4 2024.

  • Advantage Alpha Capital Partners reported no remaining Organogenesis Holdings position as of Q4 2024 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 101,558 Organogenesis Holdings shares in Q4 2024, an estimated $290K.
  • Advantage Alpha Capital Partners first reported a position in Organogenesis Holdings in Q1 2024 and held it in 3 quarters.
  • Advantage Alpha Capital Partners's Organogenesis Holdings position peaked at $1.12M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q4 2024.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2024, filed 11 Feb 2025.